![[ICO]](/icons/blank.gif){kind=icon}
![[ ]](/icons/unknown.gif){kind=icon}
![[ ]](/icons/layout.gif){kind=icon}
![[TXT]](/icons/text.gif){kind=icon}
![[DIR]](/icons/folder.gif){kind=icon}
| Name | Last modified | Size | Description |
|---|---|---|---|---|
| Parent Directory | - | ||
| simoens-report_2006-..> | 2021-05-19 15:01 | 856K | |
| Vulto Ziekenhuisapot..> | 2021-05-19 15:01 | 1.6M | |
| Van der Graaff CBG 2..> | 2021-05-19 15:01 | 1.0M | |
| Report Simon Kucher.pdf | 2021-05-19 15:01 | 423K | |
| regcoopexpanded.pdf | 2021-05-19 15:01 | 36K | |
| presentatie Apotex s..> | 2021-05-19 15:01 | 1.1M | |
| impact-van-geneesmid..> | 2021-05-19 15:01 | 8.2M | |
| hoefnagel.ppt | 2021-05-19 15:01 | 1.4M | |
| Routebeschrijving Bo..> | 2021-05-19 15:01 | 82K | |
| P_RichardsonGuidelin..> | 2021-05-19 15:01 | 131K | |
| P_RichardsonBiologic..> | 2021-05-19 15:01 | 1.0M | |
| PR 2007-06-26_price-..> | 2021-05-19 15:01 | 32K | |
| Opiniestuk PW dure m..> | 2021-05-19 15:01 | 115K | |
| N_Rossignol.pdf | 2021-05-19 15:01 | 92K | |
| M_Macdonald.pdf | 2021-05-19 15:01 | 1.2M | |
| Leidraad Informatie ..> | 2021-05-19 15:01 | 126K | |
| Koopmanschap GGG apr..> | 2021-05-19 15:01 | 247K | |
| K_Webber.pdf | 2021-05-19 15:01 | 109K | |
| J_Purves.pdf | 2021-05-19 15:01 | 363K | |
| J_Joung.pdf | 2021-05-19 15:01 | 531K | |
| J_Barth.pdf | 2021-05-19 15:01 | 217K | |
| Highlights rapport S..> | 2021-05-19 15:01 | 14K | |
| G_Woollett.pdf | 2021-05-19 15:01 | 252K | |
| G_Perry.pdf | 2021-05-19 15:01 | 313K | |
| FMD Kostenonderzoek ..> | 2021-05-19 15:01 | 8.1M | |
| FMD Cost evaluation ..> | 2021-05-19 15:01 | 8.1M | |
| FINAL EGA-pos paper ..> | 2021-05-19 15:01 | 243K | |
| Eijgelshoven Biosimi..> | 2021-05-19 15:01 | 765K | |
| E_Edery.pdf | 2021-05-19 15:01 | 253K | |
| EGA_Vision_2015.pdf | 2021-05-19 15:01 | 1.9M | |
| ega_relative-effecti..> | 2021-05-19 15:01 | 48K | |
| ega_position_WHO-INN..> | 2021-05-19 15:01 | 64K | |
| ega_biosmilarshandbo..> | 2021-05-19 15:01 | 900K | |
| ega_anticounterfeitp..> | 2021-05-19 15:01 | 84K | |
| commissiebrief-over-..> | 2021-05-19 15:01 | 92K | |
| EGA Vision 2020.pdf | 2021-05-19 15:01 | 2.7M | |
| D_Calam.pdf | 2021-05-19 15:01 | 71K | |
| C_Swann.pdf | 2021-05-19 15:01 | 234K | |
| Brussels 2007_EGA PP..> | 2021-05-19 15:01 | 1.6M | |
| Bogin symposium 2016..> | 2021-05-19 15:01 | 3.5M | |
| Bogin symposium 2016..> | 2021-05-19 15:01 | 7.4M | |
| Bogin symposium 2016..> | 2021-05-19 15:01 | 4.0K | |
| Bogin symposium 2016..> | 2021-05-19 15:01 | 3.7M | |
| Bogin symp2017 M4E w..> | 2021-05-19 15:01 | 4.8M | |
| Bogin symp 2017 KNMP..> | 2021-05-19 15:01 | 727K | |
| Bogin sym 2017 CapGe..> | 2021-05-19 15:01 | 3.7M | |
| Bogin sym 2017 Basic..> | 2021-05-19 15:01 | 1.5M | |
| Bogin drug rediscove..> | 2021-05-19 15:01 | 257K | |
| Bogin Symposium 2016..> | 2021-05-19 15:01 | 254K | |
| Bogin Symposium 2016..> | 2021-05-19 15:01 | 2.7M | |
| BOGIN sym2017 NMVO.pdf | 2021-05-19 15:01 | 1.0M | |
| Bogin bericht sept 2..> | 2021-05-19 15:01 | 183K | |
| Bogin bericht sept 2..> | 2021-05-19 15:01 | 769K | |
| Bogin bericht oktobe..> | 2021-05-19 15:01 | 386K | |
| Bogin bericht oktobe..> | 2021-05-19 15:01 | 525K | |
| Bogin bericht oktobe..> | 2021-05-19 15:01 | 187K | |
| Bogin bericht novemb..> | 2021-05-19 15:01 | 558K | |
| Bogin bericht mei 20..> | 2021-05-19 15:01 | 879K | |
| Bogin bericht maart ..> | 2021-05-19 15:01 | 415K | |
| Bogin bericht maart ..> | 2021-05-19 15:01 | 451K | |
| Bogin bericht maart ..> | 2021-05-19 15:01 | 57K | |
| Bogin bericht juni 2..> | 2021-05-19 15:01 | 439K | |
| Bogin bericht juni 2..> | 2021-05-19 15:01 | 411K | |
| Bogin bericht juni 2..> | 2021-05-19 15:01 | 477K | |
| Bogin bericht juni 2..> | 2021-05-19 15:01 | 488K | |
| Bogin bericht juni 2..> | 2021-05-19 15:01 | 430K | |
| Bogin bericht juli.pdf | 2021-05-19 15:01 | 240K | |
| Bogin bericht februa..> | 2021-05-19 15:01 | 409K | |
| Bogin bericht decemb..> | 2021-05-19 15:01 | 631K | |
| Bogin bericht decemb..> | 2021-05-19 15:01 | 421K | |
| Bogin bericht dec 20..> | 2021-05-19 15:01 | 343K | |
| Bogin bericht dec 20..> | 2021-05-19 15:01 | 99K | |
| Bogin bericht dec 20..> | 2021-05-19 15:01 | 452K | |
| bijlage 1 EC.PDF | 2021-05-19 15:01 | 7.4M | |
| Bogin bericht april ..> | 2021-05-19 15:01 | 688K | |
| Bogin bericht april ..> | 2021-05-19 15:01 | 320K | |
| Bogin bericht april ..> | 2021-05-19 15:01 | 221K | |
| Bogin bericht april ..> | 2021-05-19 15:01 | 159K | |
| Bogin bericht 2007 L..> | 2021-05-19 15:01 | 333K | |
| Bogin bericht 2007 L..> | 2021-05-19 15:01 | 356K | |
| Bogin bericht 53.pdf | 2021-05-19 15:01 | 242K | |
| Bogin Bericht 4.1.pdf | 2021-05-19 15:01 | 773K | |
| Bogin Bericht 3.4.pdf | 2021-05-19 15:01 | 776K | |
| Biosimilars conferen..> | 2021-05-19 15:01 | 3.9M | |
| BLG11845.pdf | 2021-05-19 15:01 | 498K | |
| BIO07_Programme.pdf | 2021-05-19 15:01 | 363K | |
| A_Hussain.pdf | 2021-05-19 15:01 | 6.3M | |
| Accessible, affordab..> | 2021-05-19 15:01 | 728K | |
| 20100303 IMS Generic..> | 2021-05-19 15:01 | 946K | |
| 003_EBG_FS_Biosimila..> | 2021-05-19 15:01 | 1.2M | |
| symposium/ | 2021-05-18 23:24 | - | |